Reducing Agents Decrease the Oxidative Burst and Improve Clinical Outcomes in COPD Patients: A Randomised Controlled Trial on the Effects of Sulphurous Thermal Water Inhalation
Table 2
Characteristics of the study population at the baseline.
Study population
Patients treated with inhaled sulphurous water
Patients treated with inhaled isotonic saline
P value*
40
20
20
Age
69.9 ± 1.0
69.3 ± 1.5
70.4 ± 1.4
ns
Sex (male/female)
29/11
14/6
15/5
ns
Smoking habit
Pack/years
39.7 ± 2.2
38.5 ± 3.2
41.1 ± 2.2
ns
Current smokers ()
1
1
Exsmokers ()
19
19
Nonsmokers ()
0
0
Prebronchodilator FEV1 (litre)
1.38 ± 0.06
1.41 ± 0.09
1.35 ± 0.08
ns
Prebronchodilator FEV1 (%)
54.3 ± 1.8
54.9 ± 2.6
53.6 ± 2.5
ns
Postbronchodilator FEV1 (litre)
1.48 ± 0.07
1.52 ± 0.10
1.44 ± 0.08
ns
Postbronchodilator FEV1 (%)
58.1 ± 1.8
58.9 ± 2.7
57.4 ± 2.6
ns
Reversibility to bronchodilator (litre)
0.10 ± 0.01
0.11 ± 0.01
0.09 ± 0.01
ns
Reversibility to bronchodilator (%)
6.7 ± 0.4
6.8 ± 0.5
6.6 ± 0.7
ns
Residual volume (%)
154.4 ± 7.4
149.5 ± 10.7
156.5 ± 10.3
ns
Use of long acting antimuscarin (%)
11
5
6
ns
Use of long acting β2-agonist (%)
38
18
18
ns
Beclomethasone (BDP) equivalent daily dose (μg)
1545 ± 110
1571 ± 159
1520 ± 157
ns
Use of inhaled corticosteroids ()
29
15
14
ns
CAT score
13.4 ± 0.9
13.3 ± 1.2
13.6 ± 1.4
ns
Patients treated with inhaled sulphurous water versus patients treated with inhaled isotonic saline.
